Market cap
$4 Mln
Recently Viewed
Clear All$0.56
$-0.01
(-0.89%)
As on 30-Apr-2026 11:09EDT
Market cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.3
Debt to Equity
--
Book Value
$3.9
EPS
$-2.6
Face value
--
Shares outstanding
6,599,654
CFO
$-149.69 Mln
EBITDA
$-169.08 Mln
Net Profit
$-162.42 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Galmed Pharmaceuticals - ADR
| -26.0 | 10.0 | -31.6 | -59.5 | -78.5 | -75.3 | -53.3 |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Galmed Pharmaceuticals - ADR
| -76.5 | -93.9 | -72.5 | -41.5 | -46.2 | -15.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Galmed Pharmaceuticals - ADR
|
0.6 | 4.1 | 0.0 | -10.3 | -- | -64.2 | -- | 0.3 |
| 0.4 | 6.0 | 2.4 | -11.5 | -475.0 | -117.6 | -- | 1.0 | |
| 2.6 | 293.1 | 72.8 | 35.3 | 0.0 | 44.8 | 8.2 | 2.7 | |
| 0.8 | 214.2 | 0.0 | 1,235.5 | -- | 126.2 | 0 | 0.1 | |
| 0.8 | 9.5 | 3.9 | -8.5 | -318.9 | 1107 | -- | 6.2 | |
| 71.4 | 242.8 | 19.4 | -6.1 | -30.2 | -23.7 | -- | 10.6 | |
| 23.4 | 1,173.7 | 109.8 | -153.5 | -125.8 | 268.6 | -- | 19.3 |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III... study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. Read more
Co-Founder, President, CEO & Chairman
Mr. Allen Baharaff
Co-Founder, President, CEO & Chairman
Mr. Allen Baharaff
Headquarters
Ramat Gan
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Galmed Pharmaceuticals Ltd - ADR is $0.56 (NASDAQ) as of 30-Apr-2026 11:09 EDT. Galmed Pharmaceuticals Ltd - ADR has given a return of -78.49% in the last 3 years.
Since, TTM earnings of Galmed Pharmaceuticals Ltd - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.29
|
0.19
|
|
2024
|
-0.42
|
0.20
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Galmed Pharmaceuticals Ltd - ADR are Rs 2.34 and Rs 0.41 as of 30-Apr-2026.
Galmed Pharmaceuticals Ltd - ADR has a market capitalisation of $ 4 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Galmed Pharmaceuticals Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.